X

Trial Profile

A Cancer Research UK Phase I first in man study of the novel AGC kinase inhibitor AT13148 given orally in patients with advanced solid tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT 13148 (Primary)
Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

02 Jul 2020 Results published in the Clinical Cancer Research
19 Jul 2018 Status changed from recruiting to completed.
25 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com